ACELYRIN, INC. Common Stock - Asset Resilience Ratio
ACELYRIN, INC. Common Stock (SLRN) has an Asset Resilience Ratio of 80.71% as of March 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2024)
This chart shows how ACELYRIN, INC. Common Stock's Asset Resilience Ratio has changed over time. See ACELYRIN, INC. Common Stock leverage flexibility ratio to measure the company's free cash flow as a share of total liabilities.
Liquid Assets Composition Over Time
This chart breaks down ACELYRIN, INC. Common Stock's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see ACELYRIN, INC. Common Stock (SLRN) market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $352.32 Million | 80.71% |
| Total Liquid Assets | $352.32 Million | 80.71% |
Asset Resilience Insights
- Very High Liquidity: ACELYRIN, INC. Common Stock maintains exceptional liquid asset reserves at 80.71% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
ACELYRIN, INC. Common Stock Industry Peers by Asset Resilience Ratio
Compare ACELYRIN, INC. Common Stock's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
ALTEOGEN Inc
KQ:196170 |
Biotechnology | 55.57% |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE |
Biotechnology | 47.01% |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX |
Biotechnology | 34.94% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Galapagos N.V.
AS:GLPG |
Biotechnology | 86.45% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
Annual Asset Resilience Ratio for ACELYRIN, INC. Common Stock (2021–2024)
The table below shows the annual Asset Resilience Ratio data for ACELYRIN, INC. Common Stock.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 76.15% | $373.99 Million | $491.14 Million | +8.39pp |
| 2023-12-31 | 67.76% | $503.23 Million | $742.69 Million | +53.49pp |
| 2022-12-31 | 14.27% | $47.51 Million | $332.96 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $102.30 Million | -- |
About ACELYRIN, INC. Common Stock
Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is lonigutamab, a subcutaneously delivered monoclonal antibody targeting IGF-1R, which has completed Phase 2 clinical trial for the treatment of Thyroid Eye Disease (TED). Acelyrin, Inc. was incorp… Read more